Annals of Clinical Neurophysiology

  • 제25권2호
  • /
  • Pages.66-77
  • /
  • 2023
  • /
  • 2508-691X(pISSN)
  • /
  • 2508-6960(eISSN)
대한임상신경생리학회 (The Korean Society of Clinical Neurophysiology)
권호 표지
DOI QR코드

DOI QR Code

Diagnosis and management of neurogenic orthostatic hypotension

  • Woohee Ju (Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Dong In, Sinn (Department of Neurology, School of Medicine, Stanford University)
  • 투고 : 2023.06.13
  • 심사 : 2023.10.18
  • 발행 : 2023.10.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Orthostatic hypotension is a sustained and pathological drop in blood pressure upon standing. Orthostatic hypotension can be due to non-neurogenic conditions or autonomic disorders. Impaired baroreflex-mediated vasoconstriction and insufficient release of norepinephrine play key roles in the pathophysiology of neurogenic orthostatic hypotension. Its common symptoms mainly related to inadequate cerebral blood flow include dizziness, lightheadedness, and syncope. It is crucial to differentiate neurogenic orthostatic hypotension from non-neurogenic orthostatic hypotension. For the management of neurogenic orthostatic hypotension, physicians should implement non-pharmacological methods and, if possible, reverse combined non-neurological conditions. Depending on severity of symptoms, pharmacological intervention may be tried after or with non-pharmacological methods. Its management should be individualized based on intensity of symptoms, comorbid conditions, drug side effects, and etiology. In this review, we discuss the definition, pathophysiology, clinical approach, and management of neurogenic orthostatic hypotension.

키워드

참고문헌

  1. Robertson D. The pathophysiology and diagnosis of orthostatic hypotension. Clin Auton Res 2008;18:2-7. https://doi.org/10.1007/s10286-007-1004-0
  2. Shibao C, Lipsitz LA, Biaggioni I. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens 2013;7:317-324. https://doi.org/10.1016/j.jash.2013.04.006
  3. Wieling W, Kaufmann H, Claydon VE, van Wijnen VK, Harms MPM, Juraschek SP, et al. Diagnosis and treatment of orthostatic hypotension. Lancet Neurol 2022;21:735-746. https://doi.org/10.1016/S1474-4422(22)00169-7
  4. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol 2008;7:451-458. https://doi.org/10.1016/S1474-4422(08)70088-7
  5. Lanfranchi PA, Somers VK. Arterial baroreflex function and cardiovascular variability: interactions and implications. Am J Physiol Regul Integr Comp Physiol 2002;283:R815-R826. https://doi.org/10.1152/ajpregu.00051.2002
  6. Magkas N, Tsioufis C, Thomopoulos C, Dilaveris P, Georgiopoulos G, Sanidas E, et al. Orthostatic hypotension: from pathophysiology to clinical applications and therapeutic considerations. J Clin Hypertens (Greenwich) 2019;21:546-554. https://doi.org/10.1111/jch.13521
  7. Kanjwal K, George A, Figueredo VM, Grubb BP. Orthostatic hypotension: definition, diagnosis and management. J Cardiovasc Med (Hagerstown) 2015;16:75-81. https://doi.org/10.2459/01.JCM.0000446386.01100.35
  8. Freeman R, Wieling W, Axelrod FB, Benditt DG, Benarroch E, Biaggioni I, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011;21:69-72. https://doi.org/10.1007/s10286-011-0119-5
  9. Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017;264:1567-1582. https://doi.org/10.1007/s00415-016-8375-x
  10. Freeman R, Abuzinadah AR, Gibbons C, Jones P, Miglis MG, Sinn DI. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 2018;72:1294-1309. https://doi.org/10.1016/j.jacc.2018.05.079
  11. Tzur I, Barchel D, Khateb Z, Swarka M, Izhakian S, Gorelik O. Delayed versus classic orthostatic hypotension: clinical and prognostic implications. Blood Press 2020;29:209-219. https://doi.org/10.1080/08037051.2020.1733389
  12. Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. Practical instructions for the 2018 ESC guidelines for the diagnosis and management of syncope. Eur Heart J 2018;39:e43-e80. https://doi.org/10.1093/eurheartj/ehy071
  13. Gibbons CH, Freeman R. Clinical implications of delayed orthostatic hypotension: a 10-year follow-up study. Neurology 2015;85:1362-1367. https://doi.org/10.1212/WNL.0000000000002030
  14. Byun JI, Moon J, Kim DY, Shin H, Sunwoo JS, Lim JA, et al. Delayed orthostatic hypotension: severity of clinical symptoms and response to medical treatment. Auton Neurosci 2018;213:81-85. https://doi.org/10.1016/j.autneu.2018.06.005
  15. van Wijnen VK, Harms MP, Go-Schon IK, Westerhof BE, Krediet CT, Stewart J, et al. Initial orthostatic hypotension in teenagers and young adults. Clin Auton Res 2016;26:441-449. https://doi.org/10.1007/s10286-016-0382-6
  16. Wieling W, Krediet CT, van Dijk N, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: review of a forgotten condition. Clin Sci (Lond) 2007;112:157-165. https://doi.org/10.1042/CS20060091
  17. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation 2007;115:387-397. https://doi.org/10.1161/CIRCULATIONAHA.106.634949
  18. Finucane C, O'Connell MD, Donoghue O, Richardson K, Savva GM, Kenny RA. Impaired orthostatic blood pressure recovery is associated with unexplained and injurious falls. J Am Geriatr Soc 2017;65:474-482. https://doi.org/10.1111/jgs.14563
  19. Doyle K, Lavan A, Kenny RA, Briggs R. Delayed blood pressure recovery after standing independently predicts fracture in community-dwelling older people. J Am Med Dir Assoc 2021;22:1235-1241.e1. https://doi.org/10.1016/j.jamda.2020.12.031
  20. Mol A, Slangen LRN, van Wezel RJA, Maier AB, Meskers CGM. Orthostatic blood pressure recovery associates with physical performance, frailty and number of falls in geriatric outpatients. J Hypertens 2021;39:101-106. https://doi.org/10.1097/HJH.0000000000002617
  21. van Twist DJL, Mostard GJM, Sipers WMWH. Delayed recovery from initial orthostatic hypotension: an expression of frailty in the elderly. Clin Auton Res 2020;30:105-106. https://doi.org/10.1007/s10286-019-00664-2
  22. Centi J, Freeman R, Gibbons CH, Neargarder S, Canova AO, Cronin-Golomb A. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology 2017;88:17-24. https://doi.org/10.1212/WNL.0000000000003452
  23. Robertson D, Kincaid DW, Haile V, Robertson RM. The head and neck discomfort of autonomic failure: an unrecognized aetiology of headache. Clin Auton Res 1994;4:99-103. https://doi.org/10.1007/BF01845772
  24. Bleasdale-Barr KM, Mathias CJ. Neck and other muscle pains in autonomic failure: their association with orthostatic hypotension. J R Soc Med 1998;91:355-359. https://doi.org/10.1177/014107689809100704
  25. Gibbons CH, Freeman R. Orthostatic dyspnea: a neglected symptom of orthostatic hypotension. Clin Auton Res 2005;15:40-44. https://doi.org/10.1007/s10286-005-0227-1
  26. Palma JA, Gomez-Esteban JC, Norcliffe-Kaufmann L, Martinez J, Tijero B, Berganzo K, et al. Orthostatic hypotension in Parkinson disease: how much you fall or how low you go? Mov Disord 2015;30:639-645. https://doi.org/10.1002/mds.26079
  27. Freeman R, Illigens BMW, Lapusca R, Campagnolo M, Abuzinadah AR, Bonyhay I, et al. Symptom recognition is impaired in patients with orthostatic hypotension. Hypertension 2020;75:1325-1332. https://doi.org/10.1161/HYPERTENSIONAHA.119.13619
  28. Arbogast SD, Alshekhlee A, Hussain Z, McNeeley K, Chelimsky TC. Hypotension unawareness in profound orthostatic hypotension. Am J Med 2009;122:574-580. https://doi.org/10.1016/j.amjmed.2008.10.040
  29. Shaw BH, Garland EM, Black BK, Paranjape SY, Shibao CA, Okamoto LE, et al. Optimal diagnostic thresholds for diagnosis of orthostatic hypotension with a 'sit-to-stand test'. J Hypertens 2017;35:1019-1025. https://doi.org/10.1097/HJH.0000000000001265
  30. Cremer A, Rousseau Al, Boulestreau R, Kuntz S, Tzourio C, Gosse P. Screening for orthostatic hypotension using home blood pressure measurements. J Hypertens 2019;37:923-927. https://doi.org/10.1097/HJH.0000000000001986
  31. Gibbon JR, Parry SW, Witham MD, Yarnall A, Frith J. Feasibility, reliability and safety of self-assessed orthostatic blood pressure at home. Age Ageing 2022;51:afac153.
  32. Norcliffe-Kaufmann L, Kaufmann H, Palma JA, Shibao CA, Biaggioni I, Peltier AC, et al. Orthostatic heart rate changes in patients with autonomic failure caused by neurodegenerative synucleinopathies. Ann Neurol 2018;83:522-531. https://doi.org/10.1002/ana.25170
  33. Lamotte G, Sandroni P. Updates on the diagnosis and treatment of peripheral autonomic neuropathies. Curr Neurol Neurosci Rep 2022;22:823-837. https://doi.org/10.1007/s11910-022-01240-4
  34. Freeman R. Autonomic peripheral neuropathy. Neurol Clin 2007;25:277-301. https://doi.org/10.1016/j.ncl.2007.01.001
  35. Zaeem Z, Siddiqi ZA, Zochodne DW. Autonomic involvement in Guillain-Barre syndrome: an update. Clin Auton Res 2019;29:289-299. https://doi.org/10.1007/s10286-018-0542-y
  36. Palma JA, Gonzalez-Duarte A, Kaufmann H. Orthostatic hypotension in hereditary transthyretin amyloidosis: epidemiology, diagnosis and management. Clin Auton Res 2019;29:33-44. https://doi.org/10.1007/s10286-019-00623-x
  37. Goldstein DS, Sharabi Y. Neurogenic orthostatic hypotension: a pathophysiological approach. Circulation 2009;119:139-146. https://doi.org/10.1161/CIRCULATIONAHA.108.805887
  38. Mendoza-Velasquez JJ, Flores-Vazquez JF, Barron-Velazquez E, Sosa-Ortiz AL, Illigens BW, Siepmann T. Autonomic dysfunction in α-synucleinopathies. Front Neurol 2019;10:363.
  39. Harms MP, Wesseling KH, Pott F, Jenstrup M, Van Goudoever J, Secher NH, et al. Continuous stroke volume monitoring by modelling flow from non-invasive measurement of arterial pressure in humans under orthostatic stress. Clin Sci (Lond) 1999;97:291-301. https://doi.org/10.1042/cs0970291
  40. Idiaquez JF, Idiaquez J, Casar JC, Biaggioni I. Neurogenic orthostatic hypotension. Lessons from synucleinopathies. Am J Hypertens 2021;34:125-133. https://doi.org/10.1093/ajh/hpaa131
  41. Smit AA, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of orthostatic hypotension in autonomic failure. J Physiol 1999;519:1-10. https://doi.org/10.1111/j.1469-7793.1999.0001o.x
  42. Benarroch EE. The central autonomic network: functional organization, dysfunction, and perspective. Mayo Clin Proc 1993;68:988-1001. https://doi.org/10.1016/S0025-6196(12)62272-1
  43. Cryer PE, Weiss S. Reduced plasma norepinephrine response to standing in autonomic dysfunction. Arch Neurol 1976;33:275-277. https://doi.org/10.1001/archneur.1976.00500040059009
  44. Mantovani G, Marozzi I, Rafanelli M, Rivasi G, Volpato S, Ungar A. Supine hypertension: a state of the art. Auton Neurosci 2022; 241:102988.
  45. Fanciulli A, Gobel G, Ndayisaba JP, Granata R, Duerr S, Strano S, et al. Supine hypertension in Parkinson's disease and multiple system atrophy. Clin Auton Res 2016;26:97-105. https://doi.org/10.1007/s10286-015-0336-4
  46. Jordan J, Tank J, Heusser K, Reuter H, Biaggioni I. What do we really know about supine hypertension in patients with orthostatic hypotension. Curr Opin Cardiol 2019;34:384-389. https://doi.org/10.1097/HCO.0000000000000633
  47. Fanciulli A, Jordan J, Biaggioni I, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Consensus statement on the definition of neurogenic supine hypertension in cardiovascular autonomic failure by the American Autonomic Society (AAS) and the European Federation of Autonomic Societies (EFAS) : endorsed by the European Academy of Neurology (EAN) and the European Society of Hypertension (ESH). Clin Auton Res 2018;28:355-362. https://doi.org/10.1007/s10286-018-0529-8
  48. Jordan J, Fanciulli A, Tank J, Calandra-Buonaura G, Cheshire WP, Cortelli P, et al. Management of supine hypertension in patients with neurogenic orthostatic hypotension: scientific statement of the American Autonomic Society, European Federation of Autonomic Societies, and the European Society of Hypertension. J Hypertens 2019;37:1541-1546. https://doi.org/10.1097/HJH.0000000000002078
  49. Biaggioni I. Management of orthostatic hypotension. Introduction. In: Biaggioni I, Browning K, Fink G, Jordan J, Low PA, Paton JFR, eds. Primer on the autonomic nervous system. 4th ed. Vol. 1. Oxford (UK): Elsevier; 2023;699-704.
  50. Ando Y, Asahara K, Obayashi K, Suhr O, Yonemitsu M, Yamashita T, et al. Autonomic dysfunction and anemia in neurologic disorders. J Auton Nerv Syst 1996;61:145-148. https://doi.org/10.1016/S0165-1838(96)00070-7
  51. Bolek H, Bolek EC. Orthostatic hypotension among elderly patients in Italian internal medicine wards: an observational study-comment. Intern Emerg Med 2020;15:1353-1354. https://doi.org/10.1007/s11739-020-02441-w
  52. Wieling W, van Dijk N, Thijs RD, de Lange FJ, Krediet CT, Halliwill JR. Physical countermeasures to increase orthostatic tolerance. J Intern Med 2015;277:69-82. https://doi.org/10.1111/joim.12249
  53. Palma JA, Kaufmann H. Management of orthostatic hypotension. Continuum (Minneap Minn) 2020;26:154-177.
  54. van Dijk N, de Bruin IG, Gisolf J, de Bruin-Bon HA, Linzer M, van Lieshout JJ, et al. Hemodynamic effects of leg crossing and skeletal muscle tensing during free standing in patients with vasovagal syncope. J Appl Physiol (1985) 2005;98:584-590. https://doi.org/10.1152/japplphysiol.00738.2004
  55. Krediet CT, de Bruin IG, Ganzeboom KS, Linzer M, van Lieshout JJ, Wieling W. Leg crossing, muscle tensing, squatting, and the crash position are effective against vasovagal reactions solely through increases in cardiac output. J Appl Physiol (1985) 2005;99:1697-1703. https://doi.org/10.1152/japplphysiol.01250.2004
  56. Wilcox CS, Aminoff MJ, Slater JD. Sodium homeostasis in patients with autonomic failure. Clin Sci Mol Med 1977;53:321-328. https://doi.org/10.1042/cs0530321
  57. Williams EL, Raj SR, Schondorf R, Shen WK, Wieling W, Claydon VE. Salt supplementation in the management of orthostatic intolerance: vasovagal syncope and postural orthostatic tachycardia syndrome. Auton Neurosci 2022;237:102906.
  58. Stock JM, Chelimsky G, Edwards DG, Farquhar WB. Dietary sodium and health: how much is too much for those with orthostatic disorders? Auton Neurosci 2022;238:102947.
  59. Mtinangi BL, Hainsworth R. Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. Clin Auton Res 1998;8:231-235. https://doi.org/10.1007/BF02267786
  60. Snapper H, Cheshire WP. Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome. Auton Neurosci 2022;238:102951.
  61. Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, et al. The pressor response to water drinking in humans : a sympathetic reflex? Circulation 2000;101:504-509. https://doi.org/10.1161/01.CIR.101.5.504
  62. Lipp A, Tank J, Franke G, Arnold G, Luft FC, Jordan J. Osmosensitive mechanisms contribute to the water drinking-induced pressor response in humans. Neurology 2005;65:905-907. https://doi.org/10.1212/01.wnl.0000176060.90959.36
  63. McHugh J, Keller NR, Appalsamy M, Thomas SA, Raj SR, Diedrich A, et al. Portal osmopressor mechanism linked to transient receptor potential vanilloid 4 and blood pressure control. Hypertension 2010;55:1438-1443. https://doi.org/10.1161/HYPERTENSIONAHA.110.151860
  64. May M, Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol 2011;300:R40-R46. https://doi.org/10.1152/ajpregu.00544.2010
  65. Podoleanu C, Maggi R, Brignole M, Croci F, Incze A, Solano A, et al. Lower limb and abdominal compression bandages prevent progressive orthostatic hypotension in elderly persons: a randomized single-blind controlled study. J Am Coll Cardiol 2006;48:1425-1432. https://doi.org/10.1016/j.jacc.2006.06.052
  66. Ricci F, De Caterina R, Fedorowski A. Orthostatic hypotension: epidemiology, prognosis, and treatment. J Am Coll Cardiol 2015;66:848-860. https://doi.org/10.1016/j.jacc.2015.06.1084
  67. Bourne KM, Sheldon RS, Hall J, Lloyd M, Kogut K, Sheikh N, et al. Compression garment reduces orthostatic tachycardia and symptoms in patients with postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2021;77:285-296. https://doi.org/10.1016/j.jacc.2020.11.040
  68. Lahrmann H, Cortelli P, Hilz M, Mathias CJ, Struhal W, Tassinari M. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-936. https://doi.org/10.1111/j.1468-1331.2006.01512.x
  69. Figueroa JJ, Basford JR, Low PA. Preventing and treating orthostatic hypotension: as easy as A, B, C. Cleve Clin J Med 2010; 77:298-306. https://doi.org/10.3949/ccjm.77a.09118
  70. Shibao C, Lipsitz LA, Biaggioni I. ASH position paper: evaluation and treatment of orthostatic hypotension. J Clin Hypertens (Greenwich) 2013;15:147-153. https://doi.org/10.1111/jch.12062
  71. Wright RA, Kaufmann HC, Perera R, Opfer-Gehrking TL, McElligott MA, Sheng KN, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology 1998;51:120-124. https://doi.org/10.1212/WNL.51.1.120
  72. Jankovic J, Gilden JL, Hiner BC, Kaufmann H, Brown DC, Coghlan CH, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48. https://doi.org/10.1016/0002-9343(93)90230-M
  73. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 1997;277:1046-1051. https://doi.org/10.1001/jama.1997.03540370036033
  74. Smith W, Wan H, Much D, Robinson AG, Martin P. Clinical benefit of midodrine hydrochloride in symptomatic orthostatic hypotension: a phase 4, double-blind, placebo-controlled, randomized, tilt-table study. Clin Auton Res 2016;26:269-277. https://doi.org/10.1007/s10286-016-0363-9
  75. Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of orthostatic hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992;232:139-145. https://doi.org/10.1111/j.1365-2796.1992.tb00563.x
  76. Pavy-Le Traon A, Foubert-Samier A, Ory-Magne F, Fabbri M, Senard JM, Meissner WG, et al. Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy. Eur J Neurol 2022;29:1025-1034. https://doi.org/10.1111/ene.15232
  77. Grijalva CG, Biaggioni I, Griffin MR, Shibao CA. Fludrocortisone is associated with a higher risk of all-cause hospitalizations compared with midodrine in patients with orthostatic hypotension. J Am Heart Assoc 2017;6:e006848.
  78. Palma JA, Norcliffe-Kaufmann L, Martinez J, Kaufmann H. Supine plasma NE predicts the pressor response to droxidopa in neurogenic orthostatic hypotension. Neurology 2018;91:e1539-e1544. https://doi.org/10.1212/WNL.0000000000006369
  79. Biaggioni I, Freeman R, Mathias CJ, Low P, Hewitt LA, Kaufmann H. Randomized withdrawal study of patients with symptomatic neurogenic orthostatic hypotension responsive to droxidopa. Hypertension 2015;65:101-107. https://doi.org/10.1161/HYPERTENSIONAHA.114.04035
  80. Kaufmann H, Freeman R, Biaggioni I, Low P, Pedder S, Hewitt LA, et al. Droxidopa for neurogenic orthostatic hypotension: a randomized, placebo-controlled, phase 3 trial. Neurology 2014;83:328-335. https://doi.org/10.1212/WNL.0000000000000615
  81. Hauser RA, Isaacson S, Lisk JP, Hewitt LA, Rowse G. Droxidopa for the short-term treatment of symptomatic neurogenic orthostatic hypotension in Parkinson's disease (nOH306B). Mov Disord 2015;30:646-654. https://doi.org/10.1002/mds.26086
  82. Hauser RA, Favit A, Hewitt LA, Lindsten A, Gorny S, Kymes S, et al. Durability of the clinical benefit of droxidopa for neurogenic orthostatic hypotension during 12 weeks of open-label treatment. Neurol Ther 2022;11:459-469. https://doi.org/10.1007/s40120-021-00317-5
  83. Owen R, Peng G, Gorny S, Cram C, Rowse G. Rationale and design of the neurogenic orthostatic hypotension to assess sustained effects of droxidopa therapy (RESTORE) study (P5. 131). Neurology 2016;86:131.
  84. Shibao CA, Palma JA, Celedonio JE, Martinez J, Kaufmann H, Biaggioni I. Predictors of the pressor response to the norepinephrine transporter inhibitor, atomoxetine, in neurogenic orthostatic hypotension. Hypertension 2021;78:525-531. https://doi.org/10.1161/HYPERTENSIONAHA.119.14483
  85. Ramirez CE, Okamoto LE, Arnold AC, Gamboa A, Diedrich A, Choi L, et al. Efficacy of atomoxetine versus midodrine for the treatment of orthostatic hypotension in autonomic failure. Hypertension 2014;64:1235-1240. https://doi.org/10.1161/HYPERTENSIONAHA.114.04225
  86. Kaufmann H, Vickery R, Wang W, Kanodia J, Shibao CA, Norcliffe-Kaufmann L, et al. Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial. Clin Auton Res 2021;31:699-711. https://doi.org/10.1007/s10286-021-00827-0
  87. Palma JA, Kaufmann H. Epidemiology, diagnosis, and management of neurogenic orthostatic hypotension. Mov Disord Clin Pract 2017;4:298-308. https://doi.org/10.1002/mdc3.12478
  88. Lamotte G, Lenka A. Orthostatic hypotension in parkinson disease: what is new? Neurol Clin Pract 2022;12:e112-e115. https://doi.org/10.1212/CPJ.0000000000200068
  89. Singer W, Sandroni P, Opfer-Gehrking TL, Suarez GA, Klein CM, Hines S, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-518. https://doi.org/10.1001/archneur.63.4.noc50340
  90. Schreglmann SR, Buchele F, Sommerauer M, Epprecht L, Kagi G, Hagele-Link S, et al. Pyridostigmine bromide versus fludrocortisone in the treatment of orthostatic hypotension in Parkinson's disease - a randomized controlled trial. Eur J Neurol 2017;24:545-551. https://doi.org/10.1111/ene.13260
  91. Okamoto LE, Shibao CA, Gamboa A, Diedrich A, Raj SR, Black BK, et al. Synergistic pressor effect of atomoxetine and pyridostigmine in patients with neurogenic orthostatic hypotension. Hypertension 2019;73:235-241. https://doi.org/10.1161/HYPERTENSIONAHA.118.11790